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THE CZECH BURDEN STUDY: SUBGROUP ANALYSIS (BURDEN AND 
QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY  
DISEASE EXACERBATION)
Skoupá J1, Kašák V2, Blahová M3, Cerna V1, Malý M4
1Pharma Projects, Prague, Czech Republic, 2Lerymed s.r.o., Prague, Czech Republic, 
3Thomayer University Hospital, Prague, Czech Republic, 4National Institute of Public Health, 
Prague, Czech Republic
OBJECTIVES: To estimate 6 months costs and quality of life (QoL) of patients with 
moderate to very severe COPD (GOLD criteria) who experienced a COPD exacerba-
tion in comparison with control groups of similar COPD severity without exacerba-
tion. METHODS: COPD in- and outpatients (Grade II  28; III  31; IV  31) with 
exacerbation (EXA-groups) were assessed retrospectively (3 month prior to exacerba-
tion) and prospectively (3 month after exacerbation) and compared to controls (CO-
groups) of similar disease severity but stable health (3 month retrospective assessment). 
Direct costs included hospitalization, outpatient visits, laboratory tests, imaging, medi-
cation and rehabilitation. Indirect costs included short and long term disability pay-
ments. All costs were converted to a period of 180 days; health care costs used 2008 
prices from the payer’s perspective. A validated translation of the EQ5D was com-
pleted at inclusion day (all groups) and at ﬁnal visit (EXA-groups). RESULTS: About 
18% of grade-II and 75% grade-IV exacerbations were hospitalized, resulting in 
increased costs with COPD severity (6-months median: Grade II  a846; III  a2159; 
IV  a3856; all p  0.05). Median 6-months costs in CO-groups were lower, although 
increasing from moderate to very severe COPD (Grade II  a567; III  a1610; IV  
a2084; all p  0.05). Exacerbation accounted for 8% (grade-II) to 31% (grade-IV) of 
total 6-months costs. Mean EQ5D utilities in the CO-groups and in the EXA-groups 
at ﬁnal visit were comparable (moderate: 0.589 vs.0.636; severe: 0.623 vs. 0.591; very 
severe: 0.524 vs. 0.479; NS). Mean EXA-groups utilities at inclusion were signiﬁcantly 
lower compared to ﬁnal assessment (p  0.001) and decreasing with COPD severity 
(moderate: 0.524; severe: 0.390; very severe: 0.230), reﬂecting QoL impairment during 
COPD exacerbation and natural disease course. CONCLUSIONS: The BURDEN 
study conﬁrmed for the Czech Republic a considerable economic burden of COPD. 
In accordance with international literature we found increased costs and decreased 
QoL for 1) COPD exacerbation vs. control in stable state, and 2) COPD 
progression.
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MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN 
WORKING ADULTS WITH ASTHMA IN THE U.S.
Suh DC1, Kim CM2, Kwon JW1, Choi IS1, Yang JH1, Barone JA1
1Rutgers University, Piscataway, NJ, USA, 2Catholic University, Seoul, South Korea
OBJECTIVES: To estimate annual medical and productivity costs attributable to 
obesity in working U.S. adults with asthma. METHODS: This study applied a cross 
sectional design using the 2003–2006 Medical Expenditure Panel Survey. Asthma 
patients (18–64 years old) were identiﬁed by self reported diagnosis or ICD-9-CM 
code of 493. Patients with pregnancy, malignancy, kidney dialysis, immunodeﬁciency, 
chronic obstructive pulmonary disease, low body-mass-index(BMI) 18.5, or unem-
ployed status were excluded. To investigate the impact of obesity, patients were clas-
siﬁed as normal (BMI: 18.5- 25) or obese(BMI: q30). Medical costs included all 
medical costs except for treatment costs of dental problems or injuries. Medical costs 
were estimated using a generalized linear model with a log link function and a gamma 
distribution. Loss of productivity was measured through the loss of workdays due to 
illness or injury for one year and valued using the hourly wage. Values of productivity 
loss were estimated using the two-part model. Costs attributable to obesity were esti-
mated by the differences between actual and expected costs, holding the distribution 
of covariates obtained from the normal and obese patients in the model. All costs were 
converted to 2008 U.S. dollars using price indices. RESULTS: Among a total of identi-
ﬁed 4,317 working adults with asthma, prevalence of normal weight is 34% while 
obese was 32%. The costs attributable to obesity were $2,384 (95%CI:$2,232–
$2,536) for total medical treatment costs and $215 (95%CI $189–$241) for costs 
associated with productivity loss. The missed working days attributable to obesity 
were 2.4 days/year/patient (95%CI:2.1–2.7 days). The attributable costs to medical 
and productivity loss increased as patients became older or were female patients. 
CONCLUSIONS: Obese asthma patients have signiﬁcantly higher costs associated 
with medical treatment and greater productivity loss compared to normal-weight 
asthma patients. Education aimed at weight control in asthma patients could result in 
a signiﬁcant reduction in the economic burden of treating asthma patients and enhance 
productivity.
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NEW PHARMACOECONOMIC MODEL OF ASTHMA MAINTENANCE 
TREATMENT (OPTIMA) IN RUSSIA. TO TREAT OR NOT TO TREAT: 
MAINTENANCE TREATMENT VS. NO MAINTENANCE TREATMENT
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OBJECTIVES: To compare maintenance (using the ﬁxed combination of Salmeterol 
 Fluticasone; SAL/FP) and symptomatic (no maintenance) treatments of asthma with 
a developed transparent pharmacoeconomic model. METHODS: Lack of asthma 
control leads to unscheduled resources utilization and so growth of total cost (direct 
and indirect). Algorithm of OPTIMA model calculation includes 4 steps: 1) Analysis 
of weighted average cost of maintenance medicines based on dosing, average prices 
in reimbursement, and dose distribution in assessing population, and 2) Assessment 
of cost associated with controlled and uncontrolled asthma based on number of 
unscheduled resources utilization (emergency service, outpatient visits, inpatient stay, 
and work-off days) and their unit-cost (sources–current Russian legislation, RosStat 
data) as well as QoL. 3) Detection of frequency of controlled/uncontrolled asthma in 
arms based on clinical trials data. 4) Calculation of total cost in arms (cost of drug  
% controlled * cost of controlled  % uncontrolled * cost of uncontrolled) and amount 
of saving. RESULTS: Weighted average cost of SAL/FP in Russia was 1 672 Rub 
(~ 40 EUR) per month. Cost associated with controlled and uncontrolled asthma were 
320 Rub and 62,753 Rub (~a8 and a1,400) per patient per year, respectively; QoL 
scores were 0.75 and 0.49 respectiverly. Frequency of controlled asthma in SAL/FP 
arm was 75% (GOAL study) and so 25% patients were uncontrolled. Assumed fre-
quency of controlled asthma using symptomatic treatment instead of SAL/FP  5%. 
Total costs were 35 991 Rub and 59,632 Rub (~a850 and a,1400) in maintenance and 
symptomatic arms, respectively; average QoL score were 69% and 50.3%. CONCLU-
SIONS: The model allows transparent comparisons of different asthma treatment 
approaches. Maintenance treatment with SAL/FP was superior (less cost and higher 
QoL) to symptomatic treatment.
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COST EFFECTIVENESS OF VARENICLINE COMPARED WITH EXISTING 
SMOKING CESSATION STRATEGIES IN HONG KONG
Lee KK, Lee VWY, Chow DP
The Chinese University of Hong Kong, Shatin, Hong Kong
OBJECTIVES: Smoking causes serious public health problems in Hong Kong. Effec-
tive smoking cessation strategies are required in order to cut public health budgets 
and save lives. The aim of this study is to estimate the cost effectiveness of a new 
smoking-cessation agent varenicline compared with the traditional strategies including 
bupropion, nicotine replacement treatment (NRT) and unaided cessation in Hong 
Kong. METHODS: A previously published Markov state-transition projection model 
was employed to estimate the life-long costs and effects of smoking cessation using 
varenicline, bupropion, NRT and unaided cessation from a societal perspective. Based 
on local epidemiology, a cohort of adult smokers was assumed to have a one-time 
quit attempt and was grouped by their genders and ages. Management costs and utili-
ties of ﬁve smoking related diseases including chronic obstructive pulmonary disease 
(COPD), lung cancer, coronary heart disease (CHD), stroke and asthma were studied. 
The participants of each group experienced different transition probabilities based on 
their age and disease-speciﬁc morbidity and mortality rates. Vital statistics, disease-
related morbidity and mortality rates were obtained from government statistics. Out-
comes of the study in terms of beneﬁts and costs were discounted at 5% after the ﬁrst 
year of the study. Probabilistic sensitivity analysis was performed to assess the impact 
on the model outputs of uncertainty in certain model parameters including efﬁcacies 
of the smoking cessation strategies, morbidity costs and morbidity utilities. RESULTS: 
Varenicline dominated among all the strategies with HKD106,573 (US$13,663, 
HKD7.8  USD1)/QALY when compared with bupropion; HKD246,042 
(US$31,544)/QALY with NRT and HKD41,426 (US$5,311)/ QALY with unaided 
cessation. The probabilities of varenicline being cost-effective were 77.9% when 
compared with bupropion, 69.3% with NRT and 88.3% with unaided cessation, at 
a willingness to pay of HKD50,000 (US$6410)/QALY. CONCLUSIONS: From the 
current study, varenicline appears to be a cost-effective smoking-cessation strategy 
when compared with the other existing strategies in Hong Kong.
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COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS 
PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF  
A SOUTHERN US MEDICAID AGENCY
Hampp C, Kauf TL, Saidi A, Winterstein AG
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OBJECTIVES: To calculate the cost-effectiveness of palivizumab for the prevention 
of respiratory syncytial virus (RSV) hospitalization by risk group, using real-world 
cost and incidence estimates. METHODS: Decision trees were used to calculate 
incremental cost effectiveness ratios (ICERs) as the direct medical cost required to 
prevent one RSV-related hospitalization within 8 risk groups based on indication. Risk 
groups were deﬁned by age and combinations of comorbid conditions (chronic lung 
disease [CLD], congenital heart disease [CHD], or prematurity up to 32 weeks’ ges-
tational age), in accordance with treatment guidelines. Cost and incidence parameters 
were derived from Florida Medicaid claims data (October 2004 to March 2005) using 
ICD-9 and national drug codes; palivizumab effectiveness was estimated from clinical 
trial data. RESULTS: Among 611,451 infant-months, 9,805 had claims for palivi-
zumab. Mean cost for a single dose ranged from $1347 [95% conﬁdence interval (CI): 
1336–1358] for infants under 6 months to $2096 [CI: 2081–2110] for children 1–2 
years of age. Seasonal 6-month RSV hospitalization rate ranged from 1.25% [CI: 
0.6–2.0] in children without indication to 8.13% [CI: 4.3–13.9] in premature infants 
with CHD. ICERs for palivizumab prophylaxis ranged from $246,719 [CI: 109,376–
877,173] for premature infants up to 6 months old to $1,796,002 [CI: 656,705–
9,910,719] for infants without indication. Having at least one indication resulted 
in ICER of $698,227 [CI: 290,981–2,475,180] for children 2 years of age. By com-
parison, the mean cost for RSV-related hospitalizations ranged from $4,111 [CI: 
3,891–4,330] for children without indication to $9816 [CI: 8,904–10,727] for chil-
dren with CLD. CONCLUSIONS: ICERs for palivizumab were found to be high, with 
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prophylaxis cost far exceeding the direct ﬁnancial beneﬁt of preventing hospitaliza-
tions. Factors associated with lower ICERs included young age and the presence of 
multiple indications.
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COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO 
BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY 
(SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO 
FLUTICASONE IN THE TREATMENT OF MODERATE TO  
SEVERE PERSISTENT ASTHMA UNDER THE BRAZILIAN  
SOCIETAL PERSPECTIVE
Teich V1, Niskier F1, Pimentel A2, Alameddine M2
1MedInsight, Rio de Janeiro, Brazil, 2AstraZeneca, Cotia, SP, Brazil
OBJECTIVES: To develop a cost-effectiveness analysis of formoterol associated to 
budesonide for maintenance and reliever therapy (FB SMART) versus salmeterol 
associated do ﬂuticasone (SF) in the treatment of patients with moderate to severe 
persistent asthma, under the Brazilian societal perspective. METHODS: A Markov 
model was developed to project costs and outcomes associated with disease progres-
sion of patients with moderate to severe persistent asthma receiving SMART therapy 
or SF in a one year time horizon. Weekly cycles were considered and the model 
structure consisted of four possible health states: disease control, use of oral corticoids 
(OC), hospitalization/emergency visit (H/ER) and death. The probabilities of having 
severe exacerbations (OC or H/ER) were extracted from the study by Kuna et al. All 
cause mortality rates were obtained from national epidemiological databases. Adverse 
events were not signiﬁcantly different between comparators so were excluded from 
the model. Outcomes were expressed as severe exacerbations avoided (SEA) and only 
direct medical costs were included in the analysis. Resource use during hospitalization 
was estimated based on an expert panel. Maximum prices to consumer were obtained 
for drugs, and procedure costs were extracted from the Brazilian Classiﬁcation of 
Medical Procedures (CBHPM). RESULTS: In one year, the average number of severe 
exacerbations was 0.2436 in the SMART group and 0.3928 in the SF group, resulting 
in 0.1492 severe exacerbations avoided. Total cost for the SMART and SF groups 
were R$1823.56 and R$1417.49, respectively (incremental cost  R$406.07). The 
incremental cost-effectiveness ratio in 1 year was R$2721/SEA (US$1944 2005-PPP-
index USD1.0  R$1.4). The variables that most inﬂuenced the results were the costs 
of SMART and SF therapy and the cost of hospitalization. CONCLUSIONS: SMART 
therapy reduces the risk of severe exacerbations when compared to SF in patients with 
moderate to severe persistent asthma, at a reasonable incremental cost, being a valu-
able alternative for these patients.
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IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE 
REIMBURSABLE IN THAILAND?
Thavorn K1, Chaiyakunapruk N2
1University of Toronto, Toronto, Ontario, Canada, 2Center of Pharmaceutical Outcomes 
Research, Mueng, Phitsanulok, Thailand
OBJECTIVES: Currently, no smoking cessation product is listed on National Essential 
List of Essential Medicine in Thailand. This study aimed to evaluate the cost-effective-
ness of non-nicotine smoking cessation products in Thailand from health care system 
perspective. METHODS: A Markov model was used to simulate the effects of 
smoking-cessation on cohorts of 10,000 male smokers age 40 who regularly smoked 
10–20 cigarettes a day. An incremental cost-effectiveness ratio of varenicline, bupro-
pion, and nortriptyline compared to self-quitting was estimated. Transition probabili-
ties were obtained from literature reviews, while medical care costs and utilization 
patterns were derived from a database of a Thai tertiary-care hospital and from 
the literature. The efﬁcacy of all three products was obtained from a Bayesian meta-
analysis. Costs of the medications were obtained from the Thai Drug and Medical 
Supply Information Center. Both costs and outcome were discounted at three percent. 
All costs were presented in 2008 Thai Baht. A series of sensitivity analysis including 
probabilistic sensitivity analysis, and cost-effectiveness acceptability curve were per-
formed. RESULTS: In comparison to self-quitting, using a non-nicotine smoking ces-
sation product results in cost-savings. Varenicline use results in the highest cost savings 
of 21,187 Baht or approximately US$605 and life-years gain of 0.25 years. The use 
of nortriptyline and bupropion was shown to lead to similar magnitude of both life 
years saved and cost-savings. Nortriptyline and bupropion use had cost-savings of 
11,506 Baht and 10,734 Baht, respectively. Probabilistic sensitivity analyses demon-
strate that the probability of cost-saving from using nortriptyline, varinicline, and 
bupropion for smoking cessation were 99%, 85%, and 80%, respectively. CONCLU-
SIONS: From the perspective of the health care system, using of any of the three 
products yielded cost-savings and life-year gains. These ﬁndings may persuade Thai 
policy-makers to consider including these smoking cessation products on the National 
List of Essential Medicine.
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ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITY’S 
NON-SMOKERS HEALTH PROTECTION ACT
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OBJECTIVES: To evaluate the economic impact of the Non-Smokers Health Protec-
tion Act, implemented sApril 3rd, 2008 in terms of direct employment, wages, income 
and expenses in restaurants, bars and night clubs, in Mexico City. METHODS: 
The main information source is the Monthly Services Survey, produced by Nacional 
Institute of Statistics and Geography. The monthly series begins in January 2005 
and the last available observation is for March 2009. Natural logarithms of the 
dependent variables were constructed and differences-in-differences models were 
estimated by Ordinary Least Squares (OLS) to evaluate the impact using a control 
group conformed by Nuevo León and Jalisco, states that had similar behaviour 
before the date of implementation. RESULTS: Differences-in-differences estimations 
with robust p-values in parenthesis for the effect of implementation in restaurants are 
0.144 (0.57) for direct employment; 0.78 (0.568) for wages; 0.050 (0.277) for 
income and 0.174 (0.09) for expenses. In the case of bars and night clubs: 0.004 
(.976), 0.019 (0.883), 0.025 (0.56) and 0.049 (0.552) for direct employment, wages, 
income and expenses, respectively. Coefﬁcients are non signiﬁcant statistically. CON-
CLUSIONS: With available data, we conclude that there is no statistical evidence at 
95% conﬁdence level that suggests that the implementation of the Mexico City’s 
Non-Smokers Health Protection Act has had a negative economic effect in direct 
employment, wages, income and expenses in restaurants, bars and night clubs in 
Mexico City.
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COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL  
LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE  
ALLERGIC ASTHMA
Lecomte P1, Lee CS2, Van Nooten FE3, Thompson CL4
1Novartis Pharmaceuticals, Vilvoorde, Belgium, 2Matrix45, LLC, Earlysville, VA, USA, 3United 
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OBJECTIVES: To assess, in real life conditions, the costs, effects, and cost-effective-
ness of Xolair® (omalizumab) as add-on versus conventional therapy in the manage-
ment of Belgian patients with severe persistent allergic asthma inadequately controlled. 
METHODS: The same Markov model used for omalizumab initial reimbursement 
dossier was populated with data from a Belgian observational study, i.e. PERSIST 
study (n  160), especially set up to address questions raised by the Belgian authorities 
for omalizumab re-evaluation. The model takes into account four health states and 
links effectiveness data, real life resource use, and utility data. Medical resources use 
(drug treatment, laboratory tests and procedures, physician consultations, emergency 
room visits, and hospitalisations) were collected in PERSIST and costed from the 
perspective of the health care payer (i.e. INAMI/RIZIV  patient). EQ-5D data were 
also collected during the study and used in the Markov model. RESULTS: Over a 
lifelong time horizon, the expected average numbers of life years (LYs) and QALYs 
per patient, for conventional therapy are 18.33 and 9.80, respectively. For omali-
zumab, the respective ﬁgures are 22.19 and 12.54. Over a lifelong time horizon, the 
expected average costs per patient are a44,548 and a124,726 for conventional therapy 
and omalizumab as add-on, respectively. Hence, omalizumab ICERs are a20,777/LY 
gained and a29,187/QALY gained. This compares very favourably (cf. substantial 
decrease in the ICERs) with the initial submission ICERs (i.e. a40,370/LY gained and 
a42,669/QALY gained). The sensitivity analyses performed show that results can 
somewhat vary according to the parameters changed. However, in all cases, the ICERs 
obtained with real life data are always markedly inferior to what was calculated in 
our initial submission. CONCLUSIONS: The pharmacoeconomic evaluation based on     
data from a real life Belgian study conﬁrms that omalizumab is cost-effective versus 
conventional therapy in the treatment of patients with severe persistent allergic asthma 
inadequately controlled.
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COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE 
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD) PATIENTS IN SPAIN.
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OBJECTIVES: The aim of this study is to analyze if tiotropium bromide is an efﬁcient 
alternative respect to ipratropium bromide and standard therapy, in the management 
of chronic obstructive pulmonary disease (COPD) patients in Spain. METHODS: 
Efﬁciency of the different alternative options in COPD treatment was evaluated with 
a cost-effectiveness analysis. Tiotropium bromide was compared to ipratropium 
bromide and standard therapy by means of a cost-effectiveness analysis that estimates 
life years gained (LYG) with tiotropium respect to alternatives, by combining mortality 
associated to COPD exacerbations with rates of exacerbations taken from two 
meta-analysis of head to head clinical trials. The time horizon of the study was 13 
years, the mean life expectancy in COPD patients included in the clinical trials 
with tiotropium. Uncertainty was studied by successive univariant sensitivity 
analysis of key parameters of the model and a probabilistic sensitivity analysis. 
All costs were expressed in a2008 and a 3% discount rate was applied to costs and 
effects. The analysis took the perspective of the Spanish National Health System 
(NHS). RESULTS: Incremental cost-effectiveness ratio (ICER) when treating COPD 
patients with tiotropium versus standard therapy was a2873/LYG, and in patients 
treated with tiotropium versus ipratropium bromide was a4208/LYG. Univariant 
sensitivity analysis showed that results where most sensitive to COPD severity and the 
future costs of surviving patients. CONCLUSIONS: Treating COPD patients with 
tiotropium is an efﬁcient alternative respect ipratropium bromide or standard therapy 
for the Spanish NHS.
